Global Virtual Symposium on Liquid Biopsy
Date: February 10, 2026
Format: Virtual (Central European Time)
Organized by: Impact Research Communications
The Liquid Biopsy 2026 symposium brought together leading scientists, clinicians, and industry innovators to
showcase the latest advances in circulating biomarkers, molecular diagnostics, and translational applications. The
program highlighted the transformative potential of liquid biopsy in cancer detection, monitoring, and personalized
therapy, underscoring its role as a cornerstone of precision medicine.
Plenary & Featured Sessions
-
Prof. Klaus Pantel (Germany) opened with Liquid Biopsy 2026: State-of-the-Art, providing a comprehensive
overview of current technologies and clinical integration.
-
Dr. Catherine Alix-Panabières (France) described liquid biopsy as a “medical revolution,” emphasizing its
expanding role in oncology.
-
Dr. Remond J.A. Fijneman (Netherlands) presented ctDNA applications across the colorectal cancer patient
journey, from diagnosis to relapse monitoring.
-
Dr. Valerie Taly (France) demonstrated how methylation markers combined with digital PCR enable real-time cancer
follow-up.
-
Dr. Jürgen Scheuenpflug (Germany) offered an industry perspective, addressing clinical utility, challenges, and
emerging opportunities.
Advances in Cancer Applications
-
Dr. Georg F. Weber (Germany) highlighted liquid biopsy in pancreatic cancer, advancing diagnosis and treatment
stratification.
-
Dr. Milana Frenkel-Morgenstern (Israel) expanded horizons with liquid biopsy-based detection of gene fusions.
-
Dr. Sven Borchmann (Germany) discussed pathways to bring liquid biopsy tests to patients, emphasizing European
perspectives.
- Dr. Stefano Cinti (Italy) showcased point-of-care applications, bridging diagnosis and therapy evaluation.
-
Dr. Leonora Balaj (USA) revealed insights into brain tumors through circulating biomarkers—“messages in the
blood.”
-
Dr. Melanie Janning (Germany) presented CTC apheresis as a tool for functional and single-cell oncology, moving
beyond enumeration.
Key Takeaways
- Liquid biopsy is maturing into a clinical mainstay, with applications across multiple cancer types.
-
Technological innovation—from methylation markers to digital PCR and CTC apheresis—is expanding diagnostic and
therapeutic horizons.
-
Industry perspectives highlight both opportunities and challenges in scaling liquid biopsy for routine care.
-
Global collaboration is accelerating translation from laboratory breakthroughs to patient-centered solutions.
Global Participation
Speakers represented Germany, France, Netherlands, Israel, Italy, USA, reflecting the international scope and
collaborative spirit of liquid biopsy research.
Conclusion
The Liquid Biopsy 2026 symposium underscored the field’s rapid evolution from experimental promise to clinical
reality. By integrating molecular diagnostics, point-of-care technologies, and functional analyses, liquid biopsy is
reshaping cancer care—bringing precision medicine closer to patients worldwide.
